Conference Coverage

Women recovered half their ovarian reserve 13 months after chemotherapy


 

– Women who resumed menstruating after undergoing chemotherapy for breast cancer usually recovered about half their ovarian reserve 13 months later, according to interim results from a prospective cohort study.

©BluePlanetEarth/thinkstockphotos.com
Receiving leuprolide (Lupron) during chemotherapy appeared to increase post-chemo antral follicle counts, with trends toward statistical significance at several time points, the investigators also reported.

Chemotherapy increases the risk of infertility and early menopause. But in past studies, some 70% to 80% of women regained at least some level of ovarian function after completing treatment, the researchers noted. Over the course of 6-12 months, quiescent follicles mature to the antral stage, in which exposure to follicle-stimulating hormone triggers their rapid growth and maturation. Thus, antral follicle count is an accepted marker of ovarian reserve that reliably predicts how many oocytes will be retrieved during in vitro fertilization and fertility preservation, according to the investigators.

Based on these observations, they tracked antral follicle counts over time among 199 patients who were seen for fertility preservation consultations before starting cyclophosphamide-based chemotherapy for breast cancer, and who resumed menstruating afterward. Before chemotherapy, these women had an average antral follicle count of 15, with a standard deviation of 12. They averaged 35 years of age, with a standard deviation of 5 years.

A total of 66 women returned after chemotherapy for follow-up, and underwent an average of four antral follicle counts, with a standard deviation of two, the researchers said. These measurements showed that for up to 12 months after finishing chemotherapy, patients typically had only about 14% to 25% of their baseline ovarian reserve. By month 13, however, antral follicle counts rose to an average of 52% of baseline, and remained at this level through month 18 and beyond.

Treatment with leuprolide during chemotherapy appeared to increase ovarian recovery from about month 7 onward, the researchers reported. Between 7 and 9 months after chemotherapy, antral follicle counts averaged 32% of baseline among patients who had received leuprolide, but were about 8% of baseline among patients who had not received leuprolide. Between months 13 and 18, leuprolide recipients recovered about 74% of their ovarian reserve, while other patients recovered about 35% (P = .09). Beyond month 18, leuprolide recipients recovered an average of 69% of their baseline antral follicle count and other patients recovered an average of 4 (P = .07).

“Women who did not take [leuprolide] during chemotherapy represent 75% of our study population,” the researchers said. “[These women] appeared to have lower antral follicle count recovery, despite resumption of menses, than those whose menses resumed after chemotherapy with concurrent [leuprolide].”

Dr. Letourneau reported having no relevant financial disclosures.

Recommended Reading

Early days of IVF marked by competition, innovation
MDedge ObGyn
Triptorelin doesn’t prevent ovarian failure in young women treated for lymphoma
MDedge ObGyn
Oocyte donation may up risk of preterm birth
MDedge ObGyn
European Commission’s proposed criteria for endocrine disruptors trigger multiple concerns
MDedge ObGyn
Unexplained subfertility in RA linked to periconceptional NSAID use
MDedge ObGyn
Low serum AMH predicted miscarriage after IVF
MDedge ObGyn
Psychological stress did not harm IVF outcomes
MDedge ObGyn
Resveratrol cut androgen levels in small PCOS trial
MDedge ObGyn
Resveratrol may reduce androgen levels in PCOS
MDedge ObGyn
Injectable male contraceptive on par with other reversible options
MDedge ObGyn